CDKN1A

CDKN1A

A gene on chromosome 6p21.2 that encodes a cyclin-dependent kinase inhibitor, which binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, thus acting as a regulator of cell cycle progression at G1. CDKN1A expression is controlled by p53, a tumour suppressor that mediates p53-dependent cell cycle G1-phase arrest in response to various stress stimuli. CDKN1A is specifically cleaved by CASP3-like caspases, activating CDK2 and possibly also the apoptosis pathway.
References in periodicals archive ?
MicroRNA-93 promotes ovarian granulosa cells proliferation through targeting CDKN1A in polycystic ovarian syndrome.
The selected genes included well-known oncogenes such as FOS and JUN and tumor suppressors such as CDKN1A and SERPINB5 from the top and bottom 60 FA-responsive genes (Tables 3 and 4).
The CDKN1A is involved in the regulation of transcription, apoptosis, DNA replication and repair, and cell motility (Abbas and Dutta, 2009; Cazzalini et al.
Similarly, downregulation of the cell cycle gate-keeper CDKN1A (p21) was steady but modest (Figure 5(b)) while upregulation of the DNA repair enzyme GADD45 was significant at w2 and w6.
34) These effects are mediated via CDKN1A (also known as p21/WAF1), a cyclin-dependent kinase (CDK) inhibitor.
The experimental chemotherapeutic N6-furfuryladenosine (kinetin-riboside) induces rapid ATP depletion, genotoxic stress, and CDKN1A (p21) up regulation in human cancer cell lines.
En la evaluacion genomica de las celulas MCF-7 y los potenciales blancos del miR-21 se identificaron algunos RNAm reguladores de p53, en los que se incluyen FAM3C, ACTA2, APAF1, BTG2, FAS, CDKN1A (p21), PDCD4 y SESN1, sugiriendo un vinculo funcional entre el miR-21 y la via supresora de tumor de p53 (Frankel et al.
Other genes that have emerged as significantly mutated genes in whole-exome sequencing studies of serous endometrial carcinomas are SPOP, a putative tumor suppressor gene; CDKN1A [cyclin-dependent kinase inhibitor 1A (p21, Cip1)], a bona fide cancer gene; TAF1; HCFC1R1 [host cell factor C1 regulator 1 (XPO1 dependent)]; CTDSPL [CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like]; YIPF3 (Yip1 domain family, member 3); and FAM132A (family with sequence similarity 132, member A) (17, 18).
Postmenopausal hormone therapy is associated with a reduced risk of colorectal cancer lacking CDKN1A expression.
It was also shown to increase the expression of CDKN1A (p21), a gene that inhibits prostate cancer.
A second variant identified was in a gene called CDKN1A which governs a number of tumour suppressing biological pathways.
The mechanism of action triggered by p53 when detecting a genetic error in late G1 phase consists of increasing the concentration of its protein levels, which, therefore, leads the transcription of the CDKN1A (p21) gene, 19.